| Literature DB >> 36051803 |
Ashutosh Kumar Gupta1, Munish Kohli1, Praveen Kumar Pandey1, Pankaj Dayal Dwivedi1, Vaibhav Pratap Singh1.
Abstract
Introduction: The most commonly performed surgical procedure in most oral and maxillofacial surgery practices is the removal of third molars. Postoperative pain is considered a form of acute pain due to surgical trauma with an inflammatory reaction. Materials andEntities:
Keywords: Analgesia; flupirtine; ketorolac; third molar surgery; tramadol
Year: 2022 PMID: 36051803 PMCID: PMC9426699 DOI: 10.4103/njms.NJMS_261_20
Source DB: PubMed Journal: Natl J Maxillofac Surg ISSN: 0975-5950
Distribution of study population
| Group | Analgesic | Number of case (%) |
|---|---|---|
| Group-1 | Tablet ketorolac 10 mg | 50 (33.33) |
| Group-2 | Tablet tramadol 50 mg | 50 (33.33) |
| Group-3 | Capsule flupirtine 100 mg | 50 (33.30) |
Intergroup comparison of age of study population
| Group | Number of cases | Minimum | Maximum | Median | Mean±SD | ANOVA |
|---|---|---|---|---|---|---|
| Group-1 | 50 | 20 | 50 | 40.0 | 38.76±9.25 | F=0.987 |
| Group-2 | 50 | 20 | 50 | 38.5 | 38.50±8.25 | P=0.315 |
| Group-3 | 50 | 21 | 50 | 36.00 | 38.48±8.77 | NS |
SD: Standard deviation, NS: Not significant
Intergroup comparison of gender of study population
| Gender | Group-I, n (%) | Group-II, n (%) | Group-III, n (%) | χ2, df | P |
|---|---|---|---|---|---|
| Female (n=59) | 19 (38.0) | 21 (42.0) | 19 (36) | 0.224, 2 | 0.894 |
| Male (n=91) | 31 (62.0) | 39 (58.0) | 31 (62.0) |
Intergroup comparison of site of tooth involved
| Site of tooth | Group-I, n (%) | Group-II, n (%) | Group-III, n (%) | χ2, df | P |
|---|---|---|---|---|---|
| Maxillary (n=50) | 18 (36.0) | 15 (30) | 17 (34) | 0.420, 2 | 0.81 (NS) |
| Mandibular (n=100) | 32 (64.00) | 35 (70) | 33 (66.0) |
NS: Not significant
Intergroup comparison of time of onset of analgesia (min) of study population
| Group | Number of cases | Minimum | Maximum | Median | Mean±SD | ANOVA | Group-wise comparison |
|---|---|---|---|---|---|---|---|
| Group-1 | 50 | 30 | 45 | 45.0 | 40.50±6.94 | F=0.44 | I versus II P=0.012 |
| Group-2 | 50 | 40 | 55 | 40.0 | 44.00±5.05 | I versus III P=0.687 | |
| Group-3 | 50 | 30 | 50 | 45.0 | 41.50±6.00 | II versus III P=0.100 |
SD: Standard deviation
Intergroup comparison of duration of analgesia (h) after first dose of study population
| Group | Number of cases | Minimum | Maximum | Median | Mean±SD | ANOVA | Group-wise comparison (by Tukey test) |
|---|---|---|---|---|---|---|---|
| Group-1 | 50 | 6 | 7 | 6 | 6.40±0.49 | F=7.86 | I versus II P=0.013 |
| Group-2 | 50 | 6 | 7 | 7 | 6.70±0.46 | I versus III P=0.001 | |
| Gruop-3 | 50 | 6 | 8 | 7 | 0.61±0.61 | II versus III P=0.608 |
SD: Standard deviation
Intergroup comparison of postadministration of drug (after first reporting of pain) visual analog scale score at different time intervals (KruskalWallis H-test)
| Duration/VAS | 3 h | 6 h | 24 h | 48 h | 72 h |
|---|---|---|---|---|---|
| Group-1 (mean±SD) | 3.30±0.46 | 4.50±0.68 | 2.10±0.30 | 2.0±00 | 1.58±1.11 |
| Group-2 (mean±SD) | 3.2±0.40 | 4.30±0.46 | 2.06±0.24 | 1.92±0.27 | 1.48±1.22 |
| Group-3 (mean±SD) | 3.10±0.30 | 4.20±0.40 | 2.10±0.30 | 2.0±0.0 | 1.42±1.18 |
VAS: Visual analog scale, SD: Standard deviation
Comparison between groups for postadministration of drug (after first reporting of pain) visual analog scale score at different time intervals (MannWhitney U-test)
| Group-I versus Group-II | Group-I versus Group-III | Group-II versus Group-III | ||||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| Z | P | Z | P | Z | P | |
| 3 h postoperative | 1.149 | 0.25 | 2.48 | 0.013 | 1.39 | 0.16 |
| 6 h postoperative | 2.23 | 0.025 | 3.14 | 0.002 | 1.149 | 0.25 |
| 24 h postoperative | 0.74 | 0.46 | 0.0 | 1.0 | 0.73 | 0.46 |
| 48 h postoperative | 2.03 | 0.042 | 0.0 | 1.0 | 2.03 | 0.542 |
| 72 h postoperative | 1.57 | 0.11 | 1.86 | 0.062 | 0.25 | 0.79 |
Intergroup comparison of side effects at different doses
| Side effects | Group I (n=50), n (%) | Group II (n=50), n (%) | Group III (n=50), n (%) | Statistical significance | |
|---|---|---|---|---|---|
|
| |||||
| χ2 | P | ||||
| At 1st dose | |||||
| No complication | 46 (92.0) | 43 (86.0) | 46 (92.0) | 12.433 | 0.257 |
| Diarrhea | 1 (2.0) | 0 | 0 | ||
| Hypotension | 0 | 1 (2.0) | 0 | ||
| Nausea | 2 (4.0) | 0 | 2 (4.0) | ||
| Sedation | 0 | 3 (6.0) | 2 (4.0) | ||
| Sweating | 1 (2.0) | 3 (6.0) | 0 | ||
| At 2nd dose | |||||
| No complication | 40 (80.0) | 37 (74.0) | 44 (88.0) | 15.862 | 0.322 |
| Diarrhea | 2 (4.0) | 0 | 1 (2.0) | ||
| Hypotension | 2 (4.0) | 2 (4.0) | 0 | ||
| Nausea | 3 (6.0) | 3 (6.0) | 2 (4.0) | ||
| Sedation | 0 | 3 (6.0) | 3 (6.0) | ||
| Sedation+hypotension | 0 | 1 (2.0) | 0 | ||
| Sweating | 2 (4.0) | 4 (8.0) | 0 | ||
| Sweating+nausea | 1 (2.0) | 0 | 0 | ||
| At 3rd dose | |||||
| No complication | 40 (80.0) | 35 (70.0) | 42 (84.0) | 31.017 | 0.006 |
| Constipation | 0 | 1 (2.0) | 0 | ||
| Diarrhea+hypotension | 3 (6.0) | 0 | 0 | ||
| Hypotension | 0 | 4 (8.0) | 0 | ||
| Nausea | 4 (8.0) | 1 (2.0) | 4 (8.0) | ||
| Sedation | 0 | 5 (10.0) | 3 (6.0) | ||
| Sweating | 3 (6.0) | 1 (2.0) | 1 (2.0) | ||
| Sweating+nausea | 0 | 3 (6.0) | 0 | ||
Intragroup change in pain score from 3 h of postadministration of drug (after first reporting of pain) (Wilcoxon signed-rank test)
| Group I | Group II | Group III | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
| |||||||
| Mean±SD | Z | P | Mean±SD | Z | P | Mean±SD | Z | P | |
| 6 h | 1.200±0.990 | 5.421 | <0.001 | 1.10±0.30 | 6.784 | <0.001 | 1.10±0.30 | 6.784 | <0.001 |
| 24 h | −1.200±0.404 | 6.583 | <0.001 | −1.14±0.50 | 6.364 | <0.001 | −1.00±0.14 | 7.071 | <0.001 |
| 48 h | −1.300±0.463 | 6.450 | <0.001 | −1.28±0.45 | 6.472 | <0.001 | −1.10±0.30 | 6.784 | <0.001 |
| 72 h | −1.720±1.126 | 5.730 | <0.001 | −1.72±1.29 | 5.476 | <0.001 | −1.69±1.25 | 5.329 | <0.001 |
SD: Standard deviation